Detection of an inhibiting activity for osteoclast bone resorption from human prostatic cancer cells.
An inhibiting activity for isolated osteoclasts and bone resorption was demonstrated in culture supernatants from androgen-independent, but not androgen-dependent, human prostatic cancer cell lines. It causes a dose-dependent osteoclast inhibition as quantified with a bone resorbing pit formation assay. The constitutively released activity was determined to be protein (>50 kDa) distinct from some of the known cytokines in bone resorption. The activity does not affect osteoclast morphology and viability. Time-lapse video microscopy revealed an osteoclast motility increase, disrupting their anchorage to the bone and resorbing processes. The association of the activity with androgen-independent cancer cells that disrupt bone remodeling is discussed.
Moonga
B S
BS
Regional Bone Center, Helen Hayes Hospital, New York State Department of Health, West Haverstraw 10993, USA.
Chiao
J W
JW
D000728:Androgens / Q000502:physiology; D000818:Animals; D001681:Biological Assay; D001862:Bone Resorption; D002277:Carcinoma / Q000473:pathology / Q000503:physiopathology*; D003470:Culture Media; D006801:Humans; D008297:Male; D010010:Osteoclasts / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000503:physiopathology*; D051381:Rats; D014407:Tumor Cells, Cultured
D000728:Androgens; D003470:Culture Media